BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chanyaputhipong J, Low SC, Chow PK. Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians. Int J Hepatol. 2011;2011:489342. [PMID: 21994860 DOI: 10.4061/2011/489342] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Malla RR, Kumari S, Kgk D, Momin S, Nagaraju GP. Nanotheranostics: Their role in hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2020;151:102968. [DOI: 10.1016/j.critrevonc.2020.102968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
2 Clark T, Maximin S, Meier J, Pokharel S, Bhargava P. Hepatocellular Carcinoma: Review of Epidemiology, Screening, Imaging Diagnosis, Response Assessment, and Treatment. Curr Probl Diagn Radiol. 2015;44:479-486. [PMID: 25979220 DOI: 10.1067/j.cpradiol.2015.04.004] [Cited by in Crossref: 80] [Cited by in F6Publishing: 87] [Article Influence: 11.4] [Reference Citation Analysis]
3 Song M, Cho HJ, Cho YK, Kim MY, Noh SI, Yang SH. Detecting hepatocellular carcinoma in gadoxetic-acid-enhanced hepatobiliary-phase MR imaging at 3T: comparing high and low flip angle. Jpn J Radiol 2013;31:803-11. [DOI: 10.1007/s11604-013-0255-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
4 Asemota J, Saleh M, Igbinovia O, Burns D. A Concise Review on Current Trends in Imaging and Surgical Management of Hepatocellular Carcinoma. Cureus 2020;12:e9191. [PMID: 32818122 DOI: 10.7759/cureus.9191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Gao Z, Ma T, Zhao E, Docter D, Yang W, Stauber RH, Gao M. Small is Smarter: Nano MRI Contrast Agents - Advantages and Recent Achievements. Small 2016;12:556-76. [PMID: 26680328 DOI: 10.1002/smll.201502309] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 14.3] [Reference Citation Analysis]
6 Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12003-12021 [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 41] [Article Influence: 6.1] [Reference Citation Analysis]
7 Agarwal S, Grajo JR, Fuentes-orrego JM, Abtahi SM, Harisinghani MG, Saini S, Hahn PF. Distinguishing hemangiomas from metastases on liver MRI performed with gadoxetate disodium: Value of the extended washout sign. European Journal of Radiology 2016;85:635-40. [DOI: 10.1016/j.ejrad.2015.12.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
8 Zhao W, Liu W, Liu H, Yi X, Hou J, Pei Y, Liu H, Feng D, Liu L, Li W. Preoperative prediction of microvascular invasion of hepatocellular carcinoma with IVIM diffusion-weighted MR imaging and Gd-EOB-DTPA-enhanced MR imaging. PLoS One. 2018;13:e0197488. [PMID: 29771954 DOI: 10.1371/journal.pone.0197488] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
9 Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat Med. 2012;4:19-37. [PMID: 24367230 DOI: 10.2147/hmer.s16316] [Cited by in Crossref: 39] [Cited by in F6Publishing: 132] [Article Influence: 3.9] [Reference Citation Analysis]
10 Henninger B, Petersen J, Jaschke W. [Radiological diagnosis of primary hepatic malignancy]. Wien Med Wochenschr 2013;163:113-22. [PMID: 23392810 DOI: 10.1007/s10354-013-0179-3] [Reference Citation Analysis]
11 Iannicelli E, Di Pietropaolo M, Marignani M, Briani C, Federici GF, Delle Fave G, David V. Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase. Radiol Med. 2014;119:367-376. [PMID: 24297598 DOI: 10.1007/s11547-013-0364-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
12 Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, Hiraoka A, Ikeda M, Ogasawara S, Yamashita T, Minami T, Yamakado K; Liver Cancer Study Group of Japan. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-68. [PMID: 26280007 DOI: 10.1159/000343875] [Cited by in Crossref: 274] [Cited by in F6Publishing: 272] [Article Influence: 39.1] [Reference Citation Analysis]
13 Dadfar SM, Roemhild K, Drude NI, von Stillfried S, Knüchel R, Kiessling F, Lammers T. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv Drug Deliv Rev 2019;138:302-25. [PMID: 30639256 DOI: 10.1016/j.addr.2019.01.005] [Cited by in Crossref: 386] [Cited by in F6Publishing: 314] [Article Influence: 128.7] [Reference Citation Analysis]
14 Reis MA, Baroni RH. Liver-specific magnetic resonance contrast medium in the evaluation of chronic liver disease. Einstein (Sao Paulo) 2015;13:326-9. [PMID: 26154554 DOI: 10.1590/S1679-45082015RW3159] [Reference Citation Analysis]
15 Jung SH, Yu JI, Park HC, Lim DH, Han Y. A feasibility study evaluating the relationship between dose and focal liver reaction in stereotactic ablative radiotherapy for liver cancer based on intensity change of Gd-EOB-DTPA-enhanced magnetic resonance images. Radiat Oncol J 2016;34:64-75. [PMID: 27104169 DOI: 10.3857/roj.2016.34.1.64] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
16 Piché D, Tavernaro I, Fleddermann J, Lozano JG, Varambhia A, Maguire ML, Koch M, Ukai T, Hernández Rodríguez AJ, Jones L, Dillon F, Reyes Molina I, Mitzutani M, González Dalmau ER, Maekawa T, Nellist PD, Kraegeloh A, Grobert N. Targeted T1 Magnetic Resonance Imaging Contrast Enhancement with Extraordinarily Small CoFe2O4 Nanoparticles. ACS Appl Mater Interfaces 2019;11:6724-40. [PMID: 30688055 DOI: 10.1021/acsami.8b17162] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
17 Gruber L, Rainer V, Plaikner M, Kremser C, Jaschke W, Henninger B. CAIPIRINHA-Dixon-TWIST (CDT)-VIBE MR imaging of the liver at 3.0T with gadoxetate disodium: a solution for transient arterial-phase respiratory motion-related artifacts? Eur Radiol 2018;28:2013-21. [DOI: 10.1007/s00330-017-5210-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
18 Choi SH, Lee SS, Kim SY, Park SH, Park SH, Kim KM, Hong S, Yu E, Lee M. Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Differentiation from Hepatocellular Carcinoma by Using Gadoxetic Acid–enhanced MR Imaging and Dynamic CT. Radiology 2017;282:771-81. [DOI: 10.1148/radiol.2016160639] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
19 Berks M, Little RA, Watson Y, Cheung S, Datta A, O'Connor JPB, Scaramuzza D, Parker GJM. A model selection framework to quantify microvascular liver function in gadoxetate-enhanced MRI: Application to healthy liver, diseased tissue, and hepatocellular carcinoma. Magn Reson Med 2021;86:1829-44. [PMID: 33973674 DOI: 10.1002/mrm.28798] [Reference Citation Analysis]
20 Dilger SKN, Nelson N, Venkatesh SK, Ehman EC, Fidler JL, Fletcher JG, McCollough CH, Yu L. Computed Tomography Cholangiography Using the Magnetic Resonance Contrast Agent Gadoxetate Disodium: A Phantom Study. Invest Radiol 2019;54:572-9. [PMID: 31261292 DOI: 10.1097/RLI.0000000000000580] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]